Clinical Report: Outcomes of Ublituximab in Treatment-Naïve Patients

Overview

Ublituximab demonstrated superior efficacy compared to teriflunomide in treatment-naïve patients with relapsing multiple sclerosis, showing lower annualized relapse rates and improved disability outcomes.

Background

The early initiation of high-efficacy disease-modifying therapies (DMTs) is critical in managing relapsing multiple sclerosis (RMS) to reduce disability progression and relapse rates. Ublituximab, a novel anti-CD20 monoclonal antibody, offers a promising option for treatment-naïve patients.

Data Highlights

Key Findings

• Ublituximab resulted in a significantly lower annualized relapse rate compared to teriflunomide in treatment-naïve patients (0.081 vs. 0.188, p < 0.001).
• In the early treatment subpopulation, ublituximab also showed a lower annualized relapse rate (0.130 vs. 0.334, p = 0.004).
• The rate of 12-week confirmed disability improvement was higher with ublituximab than teriflunomide (10.7% vs. 5.3%, p = 0.010).
• Ublituximab significantly reduced gadolinium-enhancing T1 lesions compared to teriflunomide (0.031 vs. 0.791, p < 0.001).
• New/enlarging T2 lesions were also significantly lower in the ublituximab group (0.390 vs. 4.144, p < 0.001).

Clinical Implications

The findings indicate that ublituximab may be a more effective treatment option for patients with relapsing multiple sclerosis who are treatment-naïve. Early initiation of high-efficacy DMTs like ublituximab could lead to better long-term outcomes in this patient population.

Conclusion

Ublituximab shows significant efficacy in treatment-naïve patients with relapsing multiple sclerosis.

Related Resources & Content

1. Ublituximab versus Teriflunomide in Relapsing Multiple Sclerosis, New England Journal of Medicine, 2022 -- Ublituximab versus Teriflunomide in Relapsing Multiple Sclerosis
2. Practice Guideline Recommendations: Disease-modifying Therapies for Adults with Multiple Sclerosis, American Academy of Neurology, 2024 -- Practice Guideline Recommendations: Disease-modifying Therapies for Adults with Multiple Sclerosis
3. The ASCO Post — Ublituximab/Ibrutinib Beneficial in Patients With Chronic Lymphocytic Leukemia
4. The ASCO Post — Update on Newer Treatments in Non-Hodgkin Lymphomas
5. The ASCO Post — Primary Analysis of ZUMA-2: Treatment of BTK Inhibitor–Naive Relapsed/Refractory Mantle Cell Lymphoma
6. The ASCO Post — Selected Abstracts From the 2016 ASH Annual Meeting
7. Practice Guideline Recommendations: Disease-modifying Therapies for Adults with Multiple Sclerosis
8. Ublituximab versus Teriflunomide in Relapsing Multiple Sclerosis | New England Journal of Medicine
9. Five Years of Ublituximab in Multiple Sclerosis: ULTIMATE I and II Open-Label Extension Study | Trials | JAMA Neurology | JAMA Network